ASCO Preview: Five Presentations To Watch Out For

AstraZeneca’s data showcase its grand strategy in lung cancer, while a trial from Gilead could provide valuable learnings for anti-TROP2 antibodies as they become more competitive - not only on efficacy, but also on safety. J&J and Legend, meanwhile, are nipping at BMS and 2seventy’s heels.

• Source: Scrip

The American Society of Clinical Oncology 2024 conference begins shortly, with thousands of abstracts slated for presentation in poster and oral sessions. Scrip will be on the ground for the meeting, taking place 31 May-4 June in Chicago, to cover the most important presentations, including multiple lung cancer datasets, the increasingly competitive space of antibody-drug conjugates (ADCs) targeting TROP2, a cancer vaccine in melanoma and cell therapy for multiple myeloma and other cancers.

The late-breaking abstracts sessions might seem an odd place to present a failed study, but Gilead Sciences, Inc. is planning to do that on 31 May with the Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By 

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

More from Conferences

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

 

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.